Non-alcoholic fatty liver disease with and without metabolic syndrome: Different long-term outcomes

Metabolism: Clinical and Experimental

Volumn 66, Issue , 2017, Pages 55-63

  Käräjämäki, Aki Juhani ^a   Bloigu, Risto ^b   Kauma, Heikki ^a   Kesäniemi, Y Antero ^a   Koivurova, Olli Pekka ^a   Perkiömäki, Juha ^a   Huikuri, Heikki ^a   Ukkola, Olavi ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF OULU   (Finland)

Author keywords

Cardiovascular diseases; Metabolic syndrome; Non alcoholic fatty liver disease; Type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; GLUCOSE; INSULIN; PATATIN LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3; PHOSPHOLIPASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROGNOSIS; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; COMPLICATION; DISEASE COURSE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; RISK FACTOR; TIME FACTOR;

ADULT; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; PROGNOSIS; RISK FACTORS; TIME FACTORS;

EID: 84979598547     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2016.06.009     Document Type: Article

References (56)

1. [1] Alberti, KG, Eckel, RH, Grundy, SM, Zimmet, PZ, Cleeman, JI, Donato, KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for Study of Obesity. Circulation 120:16 (2009), 1640–1645.
2. [2] Kassi, E, Pervanidou, P, Kaltsas, G, Chrousos, G, Metabolic syndrome; definitions and controversies. BMC Med, 9, 2011, 48.
3. [3] Gami, AS, Witt, BJ, Howard, DE, Erwin, PJ, Gami, LA, Somers, VK, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 49:4 (2007), 403–414.
4. [4] Lorenzo, C, Okoloise, M, Williams, K, Stern, MP, Haffner, SM, The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 26:11 (2003), 3153–3159.
5. [5] Hanley, AJ, Karter, AJ, Williams, K, Festa, A, D'Agostino, RB Jr., Wagenknecht, LE, et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the insulin resistance atherosclerosis study. Circulation 112:24 (2005), 3713–3721.
6. [6] Nascimbeni, F, Pais, R, Bellentani, S, Day, CP, Ratziu, V, Loria, P, et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol 59:4 (2013), 859–871.
7. [7] Targher, GT, Day, CP, Bonora, E, Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363 (2010), 1341–1350.
8. [8] Bhatia, LS, Curzen, NP, Calder, PC, Byrne, CD, Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?. Eur Heart J 33:10 (2012), 1190–1200.
9. [9] Lonardo, A, Sookoian, S, Pirola, CJ, Targher, G, Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism 65 (2016), 1136–1150.
10. [10] Hazlehurst, JM, Woods, C, Marjot, T, Cobbold, JF, Tomlinson, JW, Non-alcoholic fatty liver disease and diabetes. Metabolism 65 (2016), 1096–1108.
11. [11] Anstee, QM, Targher, G, Day, CP, Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 10:6 (2013), 330–344.
12. [12] Yki-Järvinen, H, Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2 (2014), 901–910.
13. [13] Kotronen, A, Westerbacka, J, Bergholm, R, Pietiläinen, KH, Yki-Järvinen, H, Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 92 (2007), 3490–3497.
14. [14] Machado, MV, Cortez-Pinto, H, Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterol 20:36 (2014), 12956–12980.
15. [15] Lonardo, A, Ballestri, S, Marchesini, G, Angulo, P, Loria, P, Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis 47:3 (2015), 181–190.
16. [16] Stefan, N, Kantartzis, K, Häring, HU, Causes and metabolic consequences of fatty liver. Endocr Rev 29:7 (2008), 939–960.
17. [17] Fabbrini, E, Sullivan, S, Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51:2 (2010), 679–689.
18. [18] Ballestri, S, Zona, S, Targher, G, Romagnoli, D, Baldelli, E, Nascimbeni, F, et al. Nonalcoholic fatty liver disease is associated with an almost two-fold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol 31:5 (2016), 936–944.
19. [19] Goland, S, Shimoni, S, Zornitzki, T, Knobler, H, Azoulai, O, Lutaty, G, et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol 40:10 (2006), 949–955.
20. [20] Fotbolcu, H, Yakar, T, Duman, D, Karaahmet, T, Tigen, K, Cevik, C, et al. Impairment of the left ventricular systolic and diastolic function in patients with non-alcoholic fatty liver disease. Cardiol J 17:5 (2010), 457–463.
21. [21] Fallo, F, Dalla Pozza, A, Sonino, N, Lupia, M, Tona, F, Federspil, G, et al. Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr Metab Cardiovasc Dis 19:9 (2009), 646–653.
22. [22] Hallsworth, K, Hollingsworth, KG, Thoma, C, Jakovljevic, D, MacGowan, GA, Anstee, QM, et al. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J Hepatol 58:4 (2013), 757–762.
23. [23] Guerra, F, Mancinelli, L, Angelini, L, Fortunati, M, Rappelli, A, Dessì-Fulgheri, P, et al. The association of left ventricular with metabolic syndrome is dependent of body mass index in hypertensive overweight or obese patients. PLoS One, 6(1), 2011, e16630.
24. [24] Li, NY, Yu, J, Zhang, XW, Wang, SX, Chang, P, Ding, Q, et al. Features of left ventricular hypertrophy in patients with metabolic syndrome with or without comparable blood pressure: a meta-analysis. Endocrine 43:3 (2013), 548–563.
25. [25] Mulè, G, Nardi, E, Cottone, S, Cusimano, P, Incalcaterra, F, Giandalia, ME, et al. Impact of metabolic syndrome on left ventricular mass in overweight and obese hypertensive subjects. Int J Cardiol 121:3 (2007), 267–275.
26. [26] Sookoian, S, Pirola, CJ, Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 53:6 (2011), 1883–1894.
27. [27] Rantala, AO, Kauma, H, Lilja, M, Savolainen, MJ, Reunanen, A, Kesäniemi, YA, Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. J Intern Med 245:2 (1999), 163–174.
28. [28] Valenti, L, Al-Serri, A, Daly, AK, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 51:4 (2010), 1209–1217.
29. [29] Ballestri, S, Romagnoli, D, Nascimbeni, F, Francica, G, Lonardo, A, Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. Expert Rev Gastroenterol Hepatol 9:5 (2015), 603–627.
30. [30] Airaksinen, KEJ, Koistinen, MJ, Ikäheimo, MJ, et al. Augmentation of atrial contribution to left ventricular filling in IDDM subjects assessed by Doppler echocardiography. Diabetes Care 12 (1989), 159–161.
31. [31] Troy, BL, Pombo, J, Rackley, CE, Measurement of left ventricular wall thickness and mass by echocardiography. Circulation 45 (1972), 602–611.
32. [32] Lang, RM, Badano, LP, Mor-Avi, V, Afilalo, J, Armstrong, A, Ernande, L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 16 (2015), 233–271.
33. [33] Alberti, KG, Zimmet, PZ, Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:7 (1998), 539–553.
34. [34] Korenblat, KM, Fabbrini, E, Mohammed, BS, Klein, S, Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 134:5 (2008), 1369–1375.
35. [35] Seppälä-Lindroos, A, Vehkavaara, S, Häkkinen, AM, Goto, T, Westerbacka, J, Sovijärvi, A, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 87:7 (2002), 3023–3028.
36. [36] Angelico, F, Del Ben, M, Conti, R, Francioso, S, Feole, K, Fiorello, S, et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 90:3 (2005), 1578–1582.
37. [37] Liu, H, Lu, H-Y, Nonalcoholic fatty liver disease and cardiovascular disease. World J Gastroenterol 20:26 (2014), 8407–8415.
38. [38] Chon, CW, Kim, BS, Cho, YK, Sung, KC, Bae, JC, Kim, TW, et al. Effect of nonalcoholic fatty liver disease on the development of type 2 diabetes in nonobese, nondiabetic Korean men. Gut Liver 6:3 (2012), 368–373.
39. [39] Fukuda, T, Hamaguchi, M, Kojima, T, Hashimoto, Y, Ohbora, A, Kato, T, et al. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals. Liver Int 36:2 (2016), 275–283.
40. [40] Li, WD, Fu, KF, Li, GM, Lian, YS, Ren, AM, Chen, YJ, et al. Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus. World J Gastroenterol 21:32 (2015), 9607–9613.
41. [41] Feng, RN, Du, SS, Wang, C, Li, YC, Liu, LY, Guo, FC, et al. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. World J Gastroenterol 20:47 (2014), 17932–17940.
42. [42] Kim, HJ, Kim, HJ, Lee, KE, Kim, DJ, Kim, SK, Ahn, CW, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 164:19 (2004), 2169–2175.
43. [43] Kwon, YM, Oh, SW, Hwang, SS, Lee, C, Kwon, H, Chung, GE, Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults. Am J Gastroenterol 107:12 (2012), 1852–1858.
44. [44] Leite, NC, Villela-Nogueira, CA, Cardoso, CR, Salles, GF, Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment. World J Gastroenterol 20:26 (2014), 8377–8392.
45. [45] Mantovani, A, Zoppini, G, Targher, G, Golia, G, Bonora, E, Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive type 2 diabetic individuals. J Endocrinol Invest 35:2 (2012), 215–218.
46. [46] Bonapace, S, Perseghin, G, Molon, G, Canali, G, Bertolini, L, Zoppini, G, et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care 35:2 (2012), 389–395.
47. [47] Mantovani, A, Pernigo, M, Bergamini, C, Bonapace, S, Lipari, P, Pichiri, I, et al. Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes. PLoS One, 10(8), 2015, e0135329.
48. [48] Sesti, G, Sciacqua, A, Fiorentino, TV, Perticone, M, Succurro, E, Perticone, F, Association between noninvasive fibrosis markers and cardio-vascular organ damage among adults with hepatic steatosis. PLoS One, 9(8), 2014, e104941.
49. [49] Honda, Y, Yoneda, M, Kessoku, T, Ogawa, Y, Tomeno, W, Imajo, K, et al. The characteristics of non-obese NAFLD: effect of genetic and environmental factors. Hepatol Res 46 (2016), 1011–1018.
50. [50] Shen, J, Wong, GL, Chan, HL, Chan, HY, Yeung, DK, Chan, RS, et al. PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. Aliment Pharmacol Ther 39:5 (2014), 532–539.
51. [51] Speliotes, EK, Butler, JL, Palmer, CD, Voight, BF, GIANT Consortiuim, MIGen Consortium, et al. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 52:3 (2010), 904–912.
52. [52] Park, JH, Cho, B, Kwon, H, Prilutsky, D, Yun, JM, Choi, HC, et al. I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease. Liver Int 35:12 (2015), 2537–2546.
53. [53] Petäjä, EM, Yki-Järvinen, H, Definitions of normal liver fat and the association of insulin sensitivity with acquired and genetic NAFLD — a systematic review. Int J Mol Sci, 17(5), 2016.
54. [54] Younossi, ZM, Otgonsuren, M, Venkatesan, C, Mishra, A, In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism 62 (2013), 352–360.
55. [55] Luukkonen, PK, Zhou, Y, Sädevirta, S, Leivonen, M, Arola, J, Orešič, M, et al. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. J Hepatol 64:5 (2016), 1167–1175.
56. [56] Macaluso, FS, Maida, M, Petta, S, Genetic background in nonalcoholic fatty liver disease: a comprehensive review. World J Gastroenterol 21:39 (2015), 11088–11111.